Background: At present, sufficient prognostic markers for prostate cancer (PCa) progression
Introduction
Prostate cancer (PCa) is the second most common cause of cancer and the sixth leading cause of cancer deaths among men worldwide with an estimated 899,000 new cases and 258,000 new deaths in 2008. The global PCa burden is anticipated to grow to 1.7 million new cases and 499,000 new deaths by 2030 basically due to the growth and aging of the global population [1] . Recent statistics reveal that PCa continues to remain the most commonly diagnosed lethal malignancy in men in the United States with 1 out of 6 men developing PCa and 1 out of 35 dying from it [2] .
There are now more than 240,000 men in the United States diagnosed with PCa each year [3] , and ninety percent of PCa are clinically localized and occult disease at time of diagnosis [4] .
In patients with localized PCa, the 5-year survival approximates 100%; however, in patients in whom distant metastases have occurred, the 5-year survival drops to 31% [5] . Like most other solid malignancies, PCa can metastasize to distant organs such as the liver, lungs and brain, but it has an extraordinarily high propensity for metastasizing to the bone. In one autopsy study, ~80% of the men who had died from PCa possessed bone metastases [6] .
Gleason grade is one of the most widely-used grading systems for predicting the progression of PCa. A more aggressive disease is associated with higher Gleason sum scores.
Nevertheless, the pathological grade, serum PSA value and clinical stage have some restrictions that hinder evaluation of the prognosis of PCa, although the PSA level combined with the Gleason grading system is still considered the most reliable prognostic marker [7, 8] .
Presently, adequate prognostic or predictive markers for tumor progression are still deficient.
However, some molecules are involved in diverse processes such as cell proliferation, apoptosis, cellular adhesion, tumor suppression and cell cycle-related factors have been linked to PCa outcome [9, 10] .
Several genes and signaling pathways have been implicated in PCa initiation and progression, such as p53, C-MYC, Nkx3.1, PTEN, androgen receptor (AR), and Wnt/β-Catenin [11] . Wnt/β-Catenin signaling has been implicated in both normal prostate development and in PCa progression [12] . β-Catenin forms part of the adherent junction with E-cadherin and is also a component of canonical Wnt signaling. However, the function of β-Catenin in human PCa is unclear [13] . It has been observed that β-Catenin expression and localization change during human PCa progression. However, results are inconsistent.
Several studies have seen an increase in β-Catenin expression and nuclear localization in late stage cancer samples, while others have reported a loss in nuclear expression in advanced tumors [14] [15] [16] [17] [18] .
In the current study, we examined the expression of β-Catenin in a series of Libyan PCa by immunohistochemistry (IHC). We tried to determine its value as predictive marker for metastatic potential. Additionally, the relationship between this molecular marker and known prognostic factors of serum PSA and Gleason grade were evaluated.
Patients and Methods

Clinicopatholgical features and follow up data
Archival samples of 40 prostatic adenocarcinoma were examined in the present study: A skilled pathologist confirmed all diagnosis, and the following histopathological features were recorded which include; histological type, histologic grading determined in accordance with the Gleason grading system, lymphovascular invasion, perineural invasion.
All tumors were classified using the histopathological criteria of WHO classification. The key clinicopathological data of patients are summarized in Table 1 . Where ɪ ; is the staining index, f0-f3 are the fractions of the cells showing a defined level of staining intensity (from 0 to 3). Theoretically, the index could vary between 0 and 3 [19, 20] . 8 The reproducibility of the β-catenin staining indices was tested twice by one of the observers (AE) analyzing the sections, after a few days (intra-observer variation).
Statistical analysis
Statistical analysis were performed using the SPSS® (SPSS, Inc., Chicago, USA) and STATA (Stata Corp., TX, USA) software packages (SPSS for Windows, version 18.0.3and STATA/SE 11.1). Frequency tables were analyzed using the Chi-square test, with the likelihood ratio (LR) or Fisher's exact test being used to assess the significance of the correlation between the categorical variables. Differences in the means of continuous variables were analyzed using non-parametric tests (Mann-Whitney) or Kruskall-Wallis for 2-and K-independent samples respectively. Analysis of variance was only used to derive the mean values (and 95% CI) of each individual stratum. Univariate survival analysis for the outcome measure [disease-specific survival (DSS) and disease-free survival (DFS)] was based on the Kaplan-Meier method, with log-rank (Mantel-Cox) comparison test. In all tests, p < 0.05 was regarded as statistically significant.
Results
Expression patterns of β-catenin
The expression pattern of β-catenin was predominantly membranous, in normal prostatic glands, hyperplastic prostatic glands and in tumor area as well. The expression patterns of β-catenin in PCa lesions are illustrated in the following figures respectively (Figure1-6) . The mean value of β-catenin staining index (MI) was (2.5).
Correlation of β-catenin expression with clinicopathlogical characteristics
The distribution of β-catenin expression in tumor sample in relation to clinicopathological characteristics is present in (Table2). Using different cut-off points [23, 24] .
The role of β-Catenin in prostate development is not known and its function in prostate cancer is not clearly defined [25] . Previous studies implicated β-catenin in the pathogenesis of PCa because it localizes in tumor-cell nuclei in 20% to 40% of castration resistant prostate cancer (CRPC) specimens [15, 26, 27] . More recently, a further group reported that activation of Wnt/β-catenin signaling is involved in PCa initiation and progression in a mouse model [12, 28] . Collectively, these findings imply that the Wnt canonical pathway is implicated in the pathogenesis of a subgroup of advanced PCa.
It has been observed that β-Catenin expression and localization change during human PCa progression, however, results are inconsistent [25] . Aberrant expression and localization of β-catenin in PCa are more common than predicted by Wnt pathway mutation [13, 29] .
Abnormal β-catenin expression was found in 23% of tumor samples from radical prostatectomy, and in 38% of CRPC samples, and correlates with high Gleason score [15] .
However, the detection of nuclear β-catenin in hyperplasia and in advanced tumors suggests that activation of Wnt/β-catenin signaling has a role in the premalignant stages of the disease and in the progression to CRPC [30] .
In this study, we examined the expression and localization of β-catenin protein in a subset of PCa and a number of adjacent histologically normal and hyperplastic mucosa. The results showed that a membranous staining pattern was well preserved in prostatic adenocarcinomas without detectable nuclear immunoreactivity. This finding is consistent with those of previous studies in which no nuclear β-catenin immunostaining was observed in prostatic adenocarcinomas [14, 31] .
An interesting finding in our immunohistochemical studies is that the membranous overexpression of β-catenin staining occurs mainly in cases with higher Gleason scores (>7) with high tumor grade [32, 33] . Even though, few studies [18, 34] have reported that there were no signification association between β-catenin expression and Gleason score.
This discrepancies between our results and other might be explained by the methodological differences in patient sampling, fixation and the protocols used for immunohistochemical techniques.
In the current study, we did not find any significant correlation between β-catenin expression and lymphovascular invasion. A similar finding has been reported by Morita et al [14] .
We concluded that changes in expression and cell distribution of β-catenin correlated with the progression degree of prostate adenocarcinoma, suggesting a role of this molecule as marker of progression and prognosis, even if based on a restricted number of cases.
Admittedly, supplementary studies on a larger cohorts and more heterogeneous population are necessary to validate and extend our results.
